An observational study in Breast Cancer, sponsored by Fudan University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2022-08-22.
Sponsored by Fudan University · Observational
About a half of HER2-negative breast cancer show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC samples. Patients with matched primary and relapse BC samples were included. 1299 patients were included.
12,820 studies on the registry are indexed under Breast Neoplasms; 2,920 are open to participants now.
This study's enrollment of 1,299 is above the median of 184 across 2,711 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Fudan University is the lead sponsor of 1,308 studies on the registry; 637 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with available HER2 status of primary breast cancer and relapse/metastases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with available HER2 status of primary breast cancer and relapse/metastases
Exclusion Criteria:
Patients with other malignancy
Other: no intervention
Other: no intervention
Other: no intervention
no intervention was needed
overall survival
The overall survival (OS) was defined as time from the date of initial diagnosis of recurrent/metastatic disease to the date of death from any cause
Time frame: up to 200 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.